Lipocine Inc. (LPCN) vs Neuphoria Therapeutics Inc. (NEUP)
A side-by-side comparison of Lipocine Inc. and Neuphoria Therapeutics Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
LPCN
Lipocine Inc.
$2.08HealthcareDelayed quote: Oct 6, 2026, 11:55 AM EDT
NEUP
Neuphoria Therapeutics Inc.
$3.49HealthcareDelayed quote: Oct 6, 2026, 11:43 AM EDT
Total return — LPCN vs NEUP
growth of $100 · dividends reinvested · last 5yLPCN -88.7% (-35.4%/yr)NEUP -98.0% (-54.5%/yr)LPCN compounded faster over this window
Log scale — wide-divergence pair
LPCN NEUP
LPCN vs NEUP: by the numbers
- •NEUP is the larger company ($19M vs $17M market cap).
- •Both run net losses; LPCN's is the smaller (-755.13% vs -1578.40% net margin).
Metrics side by side
Valuation
| Metric | LPCN | NEUP |
|---|---|---|
| P/S ratio | 10.93 | 16.06 |
| P/B ratio | 0.79 | 0.77 |
Profitability
| Metric | LPCN | NEUP |
|---|---|---|
| Gross margin | -334.26% | 43.54% |
| Operating margin | -524.69% | -835.53% |
| Net margin | -755.13% | -1578.40% |
| ROE | -54.45% | -75.34% |
| ROIC | -57.74% | -49.83% |
Growth (annualized)
| Metric | LPCN | NEUP |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 11.12% |
| Total return CAGR (5Y) | -34.76% | N/A |
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.